RateCaptain
  • FX Rates
  • Commodities
  • Money Market
  • Cryptocurrency
  • Corporates
  • Contact Us
No Result
View All Result
Subscribe
  • FX Rates
  • Commodities
  • Money Market
  • Cryptocurrency
  • Corporates
  • Contact Us
No Result
View All Result
Rate Captain
No Result
View All Result
Home Health

Pfizer Says Its Covid-19 Pill Will Reduce Hospitalization and Death

Rate Captain by Rate Captain
November 8, 2021
in Health
Reading Time: 4 mins read
A A
0
Share on FacebookShare on TwitterShare on WhatsappShare on Telegram

AlsoRead

Ghana Set to Start Production of Coronavirus Vaccines in January 2024

UNITAID Announces the Discovery of the Long –lasting HIV Injection

Japanese Government Donates Over 850,000 Coronavirus Vaccines to Nigeria

Drugmaker Pfizer said Friday its experimental pill designed to fight coronavirus reduced the risk of hospitalization and death for high-risk patients taking part in a trial of the drug.

The company hopes it can eventually offer the pill, given in combination with an older antiviral drug called ritonavir, to people to take at home before they get sick enough to go to the hospital.

A so-called interim analysis — done before the trial was scheduled to end — showed an 89% reduction in the risk of hospitalization or death from Covid-19 if patients got it soon enough, the company said.

The results were so striking, the company stopped the trial and is preparing to make its case to the US Food and Drug Administration for emergency authorization of the drug.

“Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic,” Pfizer CEO Albert Bourla said in a statement.

Pfizer released the results in a news release and did not provide scientists to discuss the data ahead of release. The data has not been peer reviewed or published. The company says it will share more specifics in a peer-reviewed paper and in its submission to the FDA.

The company has been testing the drug in adults with Covid-19 who are considered at high risk of progressing to severe illness. The volunteers have been randomly given either the pill combination or a placebo within three days or five days of their symptoms starting.

The pill, called Paxlovid and also known by the experimental name PF-07321332, is what’s known as a protease inhibitor. It’s designed to stop the virus from multiplying. Giving it along with ritonavir slows its breakdown in the body, the company said.

Pfizer said 0.8% of patients who got the drug combination within three days were hospitalized within four weeks — three out of 389 patients — compared to 7% of patients who got placebos, or 27 out of 385. And seven of those who got placebos died, Pfizer said. No one who got the treatment died within a month.

“Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1% of patients who received PF-07321332 (with) ritonavir were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo,” the company said.

“It means instead of 10 going to hospital, only one will go, and likely very few, if any, will die,” Bourla told CNN.

It said 19% of patients given the treatment suffered adverse events, compared to 21% who got placebo, but declined to disclose what those adverse events were.

Bourla called the results “a great day for humanity,” and noted that they came almost a year to the day of the company announcing early results for its Covid-19 vaccine, which the company released on November 9, 2020.

Bourla said the pill could save millions of lives, but he still wanted to emphasize the importance of vaccination. But vaccines are not effective 100% effective, and not everyone will get vaccinated, Bourla said, something that can lead to crowded hospitals and ICUs.

“Now we have a solution for that, and this is exactly where it fits,” Bourla said. “This is to treat those that unfortunately got the disease.”

Currently, remdesivir, sold under the brand name Veklury, is the only antiviral approved by FDA for treatment of Covid-19. It’s given by intravenous infusion, so it’s not as simple to administer as a pill.

People can also be treated with monoclonal antibodies, which are injected or infused therapies that kickstart the immune system to help fight off infection. They are not as easy to take as a pill and must be administered by a trained professional.

Merck is seeking FDA emergency use authorization for molnupiravir, an antiviral capsule people could take at home. It’s been shown to reduce the risk of hospitalization or death by about 50%. On Thursday, UK drug regulators authorized molnupiravir under the brand name Lagevrio.

Previous Post

South Korea Start-Up Firm Announce New Technology That Detects Sleep Disorder

Next Post

Naira Appreciates Against The US Dollar Closes At N414.30/$1

Related News

Ghana Set to Start Production of Coronavirus Vaccines in January 2024

by Rate Captain
March 30, 2022
0

Ghana, an African country will to start the production of coronavirus vaccines in January 2024. This is intended to provide...

UNITAID Announces the Discovery of the Long –lasting HIV Injection

by Rate Captain
March 21, 2022
0

UNITAID announced a groundbreaking development by the ViiV healthcare on the discovery of the first injection to offer long-lasting protection...

Japanese Government Donates Over 850,000 Coronavirus Vaccines to Nigeria

by Rate Captain
March 4, 2022
0

The Federal Government of Nigeria has received about 859,000 doses of AstraZeneca COVID-19 vaccines and 175 solar direct drive refrigerators...

Another Covid-19 Variant “DELTACRON” Detected in Cyprus

by Rate Captain
January 12, 2022
0

Another Covid-19 variant “Deltacron” has been detected in Cyprus. The deltacron variant is a combination strain of Covid-19 that fuses...

Next Post

Naira Appreciates Against The US Dollar Closes At N414.30/$1

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

MOMAN Debunks Rumor of Aviation Fuel Selling at N700 per Litre

Oil Marketers, Airlines reach loggerheads over local Aviation Price

May 20, 2022

Naira Depreciates at all Markets: Naira Hits N610/$1 at B2B Market

May 20, 2022

Popular Story

  • Sterling Bank to face sanctions by APCON over provocative Easter Message “Likening Christ resurrection with Agege Bread”

    Sterling Bank to face sanctions by APCON over provocative Easter Message “Likening Christ resurrection with Agege Bread”

    0 shares
    Share 0 Tweet 0
Rate Captain

RateCaptain

We bring you the most accurate in new and market data. Check our landing page for details.

  • FX Rates
  • Commodities
  • Money Market
  • Cryptocurrency
  • Corporates
  • Contact Us

Copyright © 2022 RateCaptain - All rights reserved by RateCaptain.

No Result
View All Result
  • FX Rates
  • Commodities
  • Money Market
  • Cryptocurrency
  • Corporates
  • Contact Us

Copyright © 2022 RateCaptain - All rights reserved by RateCaptain.